Interrater Reliability of the Clinical Dementia Rating in a Multicenter Trial
- 1 May 2000
- journal article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 48 (5), 558-559
- https://doi.org/10.1111/j.1532-5415.2000.tb05004.x
Abstract
OBJECTIVE: To test the interrater reliability of the Clinical Dementia Rating (CDR) in a multicenter clinical trial. DESIGN: Observational study. SETTING: Training session for a multicenter trial of milameline, a direct muscarinic agonist, in the treatment of Alzheimer's disease. PARTICIPANTS: Twenty‐four raters (physicians and nurses) familiar with drug trials and expert in the care of patients with Alzheimer's disease. METHODS: Independent scoring of the CDR using four videotaped CDR interviews. OUTCOME MEASURE: Interrater reliability, as tested by the Kappa statistic RESULTS: The overall interrater reliability was 0.62. Within the CDR domains, the global kappas ranged from 0.33 ± 0.06 to 0.88 ± 0.06. CONCLUSIONS: The data support moderate to high overall interrater reliability but show important difficulties in the reliable assessment of early dementia. J Am Geriatr Soc 48: 558–559, 2000.Keywords
This publication has 7 references indexed in Scilit:
- Clinical Dementia Rating training and reliability in multicenter studiesNeurology, 1997
- Use of global assessment measures in dementia drug trialsJournal of Clinical Epidemiology, 1994
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Comparison of Seven Psychometric Instruments Used for Evaluation of Treatment Effect in Alzheimer's DementiaNeuroepidemiology, 1990
- Reliability of Clinical Nurse Specialists in the Staging of DementiaArchives of Neurology, 1989
- Reliability of the Washington University Clinical Dementia RatingArchives of Neurology, 1988